We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Discovery and Manufacturing Strategies for Novel, Homogeneous ADC Molecules

Video   Dec 23, 2016

 

Several key learnings have emerged through application of rapid re-iterative ADC design using reactive non-natural amino acids to specifically position conjugation sites: Site-specific homogeneous molecules can improve therapeutic index preclinically and have the potential to optimize clinical impact for a given combination of antibody and warhead. Site matters. Homogeneity is required, but not sufficient, for best in class molecules. Finding the optimal site for conjugation is crucial. Beyond antibody stability, PK and attributes that optimize for internalization and cell killing in vitro, certain conjugation sites on the antibody further enhance solid tumor killing efficacy in vivo. The antibody production process has been split into two stages; First the production of the ribosome-rich extract that can now be considered a critical raw material. And secondly, use of that cell-free extract to produce nnAA containing antibodies in 10 hours from DNA. Each stage has been optimized for speed, efficiency and flexibility and now established as a viable manufacturing process: Removal of RF-1 from the extract permits very efficient production of nnAA containing Use of novel nnAAs allows complete conjugation in minutes Extracts that incorporate orthogonal tRNAs and lack RF-1 provide for efficient and flexible manufacturing.

 
 
 
Advertisement
 

Recommended Videos

Developing a New Coronavirus Vaccine

Video

Researchers at Johns Hopkins are developing a new coronavirus vaccine, but it’s no quick fix. It can take up to a year and a half for a vaccine for the virus, which causes the disease COVID-19, just to move from the lab to human trials.

WATCH NOW

COVID-19 Coronavirus Vaccine: Everything You Need to Know

Video

Professor Jonathan Heeney explains why we need a vaccine against the new COVID-19 coronavirus and how his team is using new technology developed for influenza and Ebola viruses to target the new infection.

WATCH NOW

The Coronavirus Explained

Video

In December 2019 the Chinese authorities notified the world that a virus was spreading through their communities. In the following months it spread to other countries, with cases doubling within days. This virus is the “Severe acute respiratory syndrome-related coronavirus 2”, that causes the disease called COVID-19, and that everyone simply calls "coronavirus".

WATCH NOW

 

Like what you just watched? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE